No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer

BMC Research Notes

Volumn 2, Issue , 2009, Pages

  Huang, Katie ^a,b   Dobrovic, Alexander ^a,b   Fox, Stephen ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77149164150     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-2-194     Document Type: Article

References (27)

1. Hypoxia - A key regulatory factor in tumour growth. Harris AL, Nature Reviews Cancer 2002 2 1 38 47 10.1038/nrc704 11902584
2. Targeting HIF-1 for cancer therapy. Semenza GL, Nature Reviews Cancer 2003 3 10 721 732 10.1038/nrc1187 13130303
3. Hypoxia-inducible factor 1 alpha is closely linked to an aggressive phenotype in breast cancer. Yamamoto Y Ibusuki M Okumura Y Kawasoe T, Kai K Iyama K, Iwase H, Breast Cancer Research and Treatment 2008 110 3 465 475 10.1007/s10549-007-9742-1 17805961
4. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Unruh A Ressel A, Mohamed HG Johnson RS, Nadrowitz R Richter E, Katschinski DM Wenger RH, Oncogene 2003 22 21 3213 3220 10.1038/sj.onc.1206385 12761491
5. Breast tumour angiogenesis. Fox SB Generali DG Harris AL, Breast Cancer Research 2007 9 6 11 10.1186/bcr1796
6. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. King A Selak MA Gottlieb E, Oncogene 2006 25 34 4675 4682 10.1038/sj.onc.1209594 16892081
7. Mitochondrial tumour suppressors: a genetic and biochemical update. Gottlieb E Tomlinson IP, Nat Rev Cancer 2005 5 11 857 866 10.1038/nrc1737 16327764
8. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Selak MA Armour SM, MacKenzie ED Boulahbel H, Watson DG Mansfield KD, Pan Y Simon MC, Thompson CB Gottlieb E, Cancer Cell 2005 7 1 77 85 10.1016/j.ccr.2004.11.022 15652751
9. A role for mitochondrial enzymes in inherited neoplasia and beyond. Eng C Kiuru M, Fernandez MJ Aaltonen LA, Nat Rev Cancer 2003 3 3 193 202 10.1038/nrc1013 12612654
10. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Pollard PJ Wortham NC Tomlinson IPM, Annals of Medicine 2003 35 8 634 635 10.1080/07853890310018458
11. On the association of succinate dehydrogenase mutations with hereditary paraganglioma. Baysal BE, Trends Endocrinol Metab 2003 14 10 453 459 10.1016/j.tem.2003.08.004 14643060
12. Sensitive Melting Analysis after Real Time-Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Kristensen LS Mikeska T, Krypuy M Dobrovic A, Nucleic Acids Research 2008 36 7 42 10.1093/nar/gkn113 18344521
13. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment of methylation. Wojdacz TK Dobrovic A, Nucleic Acids Research 2007 35 6 41 10.1093/nar/gkm013 17289753
14. Investigation of the role of SDHB inactivation in sporadic phaeochromocytoma and neuroblastoma. Astuti D Morris M, Krona C Abel F, Gentle D Martinsson T, Kogner P Neumann HP, Voutilainen R Eng C, et al. Br J Cancer 2004 91 10 1835 1841 10.1038/sj.bjc.6602202 15505628
15. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Dammann R Yang G Pfeifer GP, Cancer Res 2001 61 7 3105 3109 11306494
16. Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy. Horne HN Lee PS, Murphy SK Alonso MA, Olson JA Jr Marks JR, Mol Cancer Res 2009 7 2 199 209 10.1158/1541-7786.MCR- 08-0314 19208741
17. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. Bos R Zhong H, Hanrahan CF Mommers ECM, Semenza GL Pinedo HM, Abeloff MD Simons JW, van Diest PJ Wall, van der E Journal of the National Cancer Institute 2001 93 4 309 314 10.1093/jnci/93.4.309 11181778
18. Hypoxia and breast cancer: prognostic and therapeutic implications. Lundgren K Holm C Landberg G, Cellular and Molecular Life Sciences 2007 64 24 3233 3247 10.1007/s00018-007-7390-6 17957335
19. HIF-1 alpha and CA IX staining in invasive breast carcinomas: Prognosis and treatment outcome. Trastour C Benizri E Ettore F Ramaioli A, Chamorey E Pouyssegur J, Berra E, International Journal of Cancer 2007 120 7 1451 1458 10.1002/ijc.22436 (Pubitemid 46355379)
20. Role of hypoxia-inducible factor-1 alpha as a cancer therapy target. Patiar S Harris AL, Endocrine-Related Cancer 2006 13 61 S75 10.1677/erc.1.01290 17259560
21. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Niemann S Muller U, Nat Genet 2000 26 3 268 270 10.1038/81551 11062460
22. Germline SDHD mutation in familial phaeochromocytoma. Astuti D Douglas F Lennard TW Aligianis IA, Woodward ER Evans DG, Eng C Latif F, Maher ER, Lancet 2001 357 9263 1181 1182 10.1016/S0140-6736(00)04378-6 11323050
23. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Tomlinson IP Alam NA, Rowan AJ Barclay E, Jaeger EE Kelsell D, Leigh I Gorman P, Lamlum H Rahman S, et al. Nat Genet 2002 30 4 406 410 10.1038/ng849 11865300
24. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Pollard PJ Briere JJ, Alam NA Barwell J, Barclay E Wortham NC, Hunt T Mitchell M, Olpin S Moat SJ, et al. Hum Mol Genet 2005 14 15 2231 2239 10.1093/hmg/ddi227 15987702
25. Cells silenced for SDHB expression display characteristic features of the tumor phenotype. Cervera AM Apostolova N Crespo FL Mata M, McCreath KJ, Cancer Res 2008 68 11 4058 4067 10.1158/0008-5472.CAN-07-5580 18519664
26. No evidence for involvement of SDHD in neuroblastoma pathogenesis. De Preter K Vandesompele J, Hoebeeck J Vandenbroecke C, Smet J Nuyts A, Laureys G Combaret V, Van Roy N Roels F, et al. BMC Cancer 2004 4 55 10.1186/1471-2407-4- 55 15331017
27. Promoter hypermethylation profile of kidney cancer. Dulaimi E Ibanez de Caceres I, Uzzo RG Al-Saleem T, Greenberg RE Polascik TJ, Babb JS Grizzle WE, Cairns P, Clin Cancer Res 2004 10 12 Pt 1 3972 3979 10.1158/1078-0432.CCR-04- 0175 15217927